Ebola Vaccine Trial 'Tumaini' Begins in Congo as Kenya Reports Second Death

The first Ebola vaccine trial of the current outbreak has begun in the Democratic Republic of Congo — on the same day Kenya confirmed its second death from the virus. The trial, named Tumaini — Swahili for "hope" — is the first serious attempt to answer the question that has haunted this outbreak for months: does any existing vaccine work against the strain actually spreading?

What the Tumaini trial will test

On Friday, the first participants were vaccinated in Bunia, the capital of Ituri province in north-eastern DR Congo, the epicentre of the outbreak. The trial is coordinated by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from the World Health Organization and the Congolese health ministry. Its first candidate is Ervebo, a vaccine approved against the more common Zaire strain of Ebola — not the Bundibugyo strain behind this outbreak. "This trial will help us understand whether any of the vaccine candidates designed for Bundibugyo virus work," WHO director-general Tedros Adhanom Ghebreyesus said, according to Al Jazeera.

Tumaini is built as a single trial framework that can test several vaccines. Two Bundibugyo-specific candidates are expected to join shortly: an Oxford ChAdOx1 adenoviral-vector vaccine and an mRNA vaccine from Moderna, both backed by CEPI. Until now, there has been no approved vaccine against Bundibugyo at all — the gap that has made this outbreak, declared in May and now DR Congo's 17th and worst, so hard to fight. It has since recorded more than 9,700 cases and more than 4,600 deaths, and has spread to four countries, the widest geographic spread of any Ebola outbreak on the continent.

Kenya's second death — and why officials say it is contained

Kenya's health ministry reported its second Ebola death on October 23: a 65-year-old woman, the country's third confirmed case, who was a close relative of Kenya's first patient and had direct contact with him. She was isolated before symptoms appeared on October 13 and moved to a specialist treatment area the same day, EconoTimes reports. Kenya now has nine confirmed cases in total, including two deaths, with seven patients in care at two isolation facilities. Officials say all cases trace to known contacts, with no evidence of community spread, and that 135 contacts had been traced as of October 22.

The two halves of this story belong together. Kenya's cluster shows what contact tracing and isolation can contain; Congo's trial shows what science still cannot yet do — protect people before exposure. Our earlier coverage tracked Kenya's outbreak growing to seven cases and the virus reaching an eighth Congolese province. Tumaini will not change the numbers overnight — trials take time, and Ervebo may not cross-protect at all — but for the first time in this outbreak, there is a structured test of whether a vaccine can. That, in an epidemic with no approved vaccine for its strain, is genuinely new.

This article is general information only and is not medical advice.